Skip to content

FDA decides to revoke Avastin for breast cancer

The U.S. Food and Drug Administration has withdrawn its approval of Avastin, a drug commonly used in patients with advanced breast cancer. Dr. Leah Cream, an assistant professor of medicine at Penn State Hershey Cancer Institute, gives her reaction to the decision and explains its significance for breast cancer patients and their doctors.

If you're having trouble accessing this content, or would like it in another format, please email the Penn State College of Medicine web department.